Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Chuke Nwachuku"'
Autor:
Horia Marginean, Barry R. Davis, Chuke Nwachuku, Udho Thadani, Nathan D. Wong, Joshua I. Barzilay, Richard A. Dart, Jan Basile, Charles Baimbridge, Jackson T. Wright, Paul K. Whelton, Henry R. Black
Publikováno v:
Diabetes Care. 31:353-360
OBJECTIVE—Optimal initial antihypertensive drug therapy in people with the metabolic syndrome is unknown. RESEARCH DESIGN AND METHODS—We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78ec3711a6fac9457dc7e1b05915fbf0
https://doi.org/10.2337/dc07-1452
https://doi.org/10.2337/dc07-1452
Autor:
Wenke Hwang, Hal H. Atkinson, Patrick J. O'Connor, G. John Chen, Chuke Nwachuku, Lois A. Katz, David C. Aron, K.M. Venkat Narayan, Ping Zhang, Roger T. Anderson, Amiram Gafni, Mark Sullivan, Arnaud Bastien, Patricia Feeney
Publikováno v:
The American Journal of Cardiology. 99:S90-S102
Diabetes mellitus affects not only life expectancy but also quality of life. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial's health-related quality of life (HRQOL) and cost-effectiveness components will enable the assessment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4df49d1d1b5bd41e3acd341036431ae3
https://doi.org/10.1016/j.amjcard.2007.03.027
https://doi.org/10.1016/j.amjcard.2007.03.027
Autor:
Linda B. Piller, Lara M. Simpson, Barry R. Davis, Paula T. Einhorn, Barry M. Massie, William C. Cushman, Chuke Nwachuku, Henry R. Black, Daniel Levy
Publikováno v:
American Heart Journal. 153:42-53
Background ALLHAT, a randomized, double-blind, active-controlled hypertension treatment trial in 42,418 patients, reported that a thiazide-type diuretic (chlorthalidone) was superior to a calcium channel blocker (amlodipine), an angiotensin-convertin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbd682268f8b9d699b976b02459c5c9a
https://doi.org/10.1016/j.ahj.2006.10.012
https://doi.org/10.1016/j.ahj.2006.10.012
Autor:
Michael H. Alderman, William C. Cushman, Henry R. Black, Barry R. Davis, Richard A. Dart, Chuke Nwachuku, Steven A. Atlas, Paul K. Whelton, Richard H. Grimm, Jan Basile, James V. Felicetta, Aloysius B. Cuyjet, Udho Thadani, Lara M. Simpson, Syed Z. A. Jafri, Frans H. H. Leenen, L. Julian Haywood, Michael A. Proschan, Jackson T. Wright
Publikováno v:
Hypertension. 48:374-384
The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) provides a unique opportunity to compare the long-term relative safety and efficacy of angiotensin-converting enzyme inhibitor and calcium channel blocker–init
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9da57b8041c8df38e29bb25a6c26492f
https://doi.org/10.1161/01.hyp.0000231662.77359.de
https://doi.org/10.1161/01.hyp.0000231662.77359.de
Autor:
Linda B. Piller, Henry R. Black, Suzanne Oparil, Barry R. Davis, Chuke Nwachuku, Jeffrey L. Probstfield, Charles E. Ford, Tamrat M. Retta
Publikováno v:
J Clin Hypertens (Greenwich)
Angioedema is a rare, potentially life-threatening condition that has been associated with angiotensin-converting enzyme inhibitors since their introduction in the 1980s. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b6acab5196d5849337fc6838b44d31
https://doi.org/10.1111/j.1524-6175.2006.05689.x
https://doi.org/10.1111/j.1524-6175.2006.05689.x
Autor:
Gabriel B. Habib, Vasilios Papademetriou, David Gordon, Brian Montgomery Sumner, Chuke Nwachuku, Charles E. Ford, Nathan D. Wong, Linda B. Piller, Therese S. Geraci, Puneet Narayan, Thomas J. Hartney, Efrain Reisin, L. Julian Haywood
Publikováno v:
J Clin Hypertens (Greenwich)
The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) consisted of 42,418 participants randomized to one of four antihypertensive treatment groups: chlorthalidone, amlodipine, lisinopril, or doxazosin. A subset of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32fba9cd010b680bab2dbda0d785c1f3
https://doi.org/10.1111/j.1524-6175.2003.03163.x
https://doi.org/10.1111/j.1524-6175.2003.03163.x
Autor:
Angela Williard, Sara L. Pressel, Lara M. Simpson, Connie Kingry, Karen L. Margolis, Michael A. Proschan, Juan Alzate, Frans H. H. Leenen, Jeff D. Williamson, Robert Pospisil, John H. Eckfeldt, David C. Goff, I. Kay Dunn, L. Julian Haywood, Suzanne Oparil, Gail T. Louis, Michael H. Alderman, Paul K. Whelton, R. L Sue Ferguson, Anne Juratovac, Brenda Jaeger, David Gordon, Pamela Ragusa, Richard S. Crow, David A. Calhoun, Christine Nelson, Jeanne Russo, William C. Cushman, Therese S. Geraci, Linda B. Piller, Sharon Feldman, Tracy Lucente, Gail Barone, Judy Bettencourt, Kim Jenkins, Peggy McDowell, Lillian Carroll, Jeffrey A. Cutler, Henry R. Black, Jackson T. Wright, Sandra M. Walsh, Joe Blanton, Sheila Sullivan, Rudy Christian, John Pelosi, Richard H. Grimm, Joanna Tanner, Curt D. Furberg, Barbara DeLeon, Janice Johnson, Paula Einhom, Leslie Ann Holland-Klemme, Barry R. Davis, Mahboob Rahman, Jeffrey L. Probstfield, Chuke Nwachuku, Charles E. Ford
Publikováno v:
JAMA: The Journal of the American Medical Association. 288:2981-2997
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7cc7c3bb46bd6d64a64ff24495784d3
https://doi.org/10.1001/jama.288.23.2981
https://doi.org/10.1001/jama.288.23.2981
Autor:
Chuke Nwachuku, Robert J. Weiss, William C. Cushman, Sandra M. Walsh, Michael H. Alderman, Karen L. Margolis, Joanne Holland, Barry R. Davis, Linda B. Piller, Charles E. Ford, Henry R. Black, Bruce P. Hamilton, Vasilios Papademetriou, Jeffrey L. Probstfield, Richard H. Grimm, Judy Bettencourt, Jackson T. Wright, Jeffrey A. Cutler
Publikováno v:
The Journal of Clinical Hypertension. 4:393-404
Context Blood pressure control ( Objective To determine the success and predictors of blood pressure control in a large hypertension trial involving a multiethnic population in diverse practice settings. Design The Antihypertensive and Lipid-Lowering
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::429da63097f4380576e1f1d75095c746
https://doi.org/10.1111/j.1524-6175.2002.02045.x
https://doi.org/10.1111/j.1524-6175.2002.02045.x
Autor:
Joseph P. Frolkis, Frans H. H. Leenen, Pedro J. Colon, Rebecca Letterer, Grant E Deger, William C. Cushman, Debra Egan, Tracy Lucente, Sara L. Pressel, Barry R. Davis, Chuke Nwachuku, Jonathan N. Tobin, Joshua I. Barzilay, Jackson T. Wright, Sandra M. Walsh
Publikováno v:
Controlled Clinical Trials. 22:659-673
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a randomized clinical outcome trial of antihypertensive and lipid-lowering therapy in a diverse population (including substantial numbers of women and minorit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7682f65099995b64efa681eb4cb4cf1
https://doi.org/10.1016/s0197-2456(01)00176-3
https://doi.org/10.1016/s0197-2456(01)00176-3
Autor:
Barbara Kimmel, Sara L. Pressel, Barry R. Davis, Chuke Nwachuku, Charles E. Ford, Christine Lusk, Linda B. Piller, Jackson T. Wright, Judy Bettencourt, Lara M. Simpson, Therese S. Geraci, Curt D. Furberg, Connie Kingry, Heather Parks
Publikováno v:
Controlled Clinical Trials. 22:29-41
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a randomized, practice-based trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI). The double-blind, active-controlled component of ALLHAT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b94a73d1b161378777a37badad5d5f3
https://doi.org/10.1016/s0197-2456(00)00109-4
https://doi.org/10.1016/s0197-2456(00)00109-4